| 2022-SINT-69726 | |
| Researchers at Purdue University have designed molecules to concurrently inhibit two proteins important in tumorigenesis, MNK1/2 and p706SK. Pharmaceutical companies have pursued MNK1/2 and p706SK as individual targets; however, drugs targeting these proteins performed poorly as monotherapies. By inhibiting both MNK1/2 and p706SK with a single molecule, the Purdue researchers' orally bioavailable compounds potently inhibit several solid tumor cancer cell lines, including breast, ovarian, lung, and colon cancer cells. Technology Validation: At 200 nM, one of the drugs designed by the researchers completely inhibited the growth of Caki-1 (renal cancer) and MDA-MB-231 (breast cancer) cells. Compounds were tested against the NCI-60 cell line panel. Advantages - Targets two oncogenic proteins with a single molecule - Effective against multiple solid tumor cell lines - Orally bioavailable Applications - Anticancer drugs |
|
|
|
|
Apr 6, 2022
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
